Galanin
What the Research Actually Shows
Human: 1 studies, 3 groups · Animal: 2 · In Vitro: 0
The 29-amino-acid peptide that marks your brain's sleep-switch neurons—proven by optogenetics to initiate sleep and trigger the body cooling that precedes it, with a single human IV study showing REM enhancement and a hint of antidepressant effect
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Deep in your hypothalamus, a small cluster of neurons acts as the brain's sleep switch—and galanin is the peptide that defines them. These VLPO galanin neurons shut down the wake-promoting centers of the brain and simultaneously trigger the body cooling that precedes sleep onset. A 2018 optogenetics study proved this definitively by switching these neurons on and off with light. One small human study gave galanin intravenously to healthy young men and found it increased REM sleep and showed a possible antidepressant effect. That is the entire human evidence base: roughly 12 people in one study. The biology is important. The clinical data barely exists. No drug company is developing a galanin-based sleep therapy.
Every night, your body drops its core temperature by about 1–2°F before sleep onset. This is not a coincidence or a side effect—it is an active physiological process, and the neurons responsible for it are the same ones that initiate sleep itself. They are the galanin-producing neurons of the ventrolateral preoptic area (VLPO), and they are the closest thing the brain has to a sleep switch.
Galanin is a 29-amino-acid neuropeptide (30 in non-primate mammals) with a remarkably broad distribution and diverse functions—it regulates feeding, pain, seizures, mood, and cognition in addition to sleep. But its role in the VLPO is what places it in Cluster J. A landmark 2018 Nature Communications paper (Kroeger et al.; PMID 30297727) used optogenetic tools to demonstrate that activating VLPO galanin neurons at low frequencies promotes sleep while simultaneously activating thermoregulatory circuits that cause heat loss—explaining the well-known observation that body cooling precedes and facilitates sleep onset.
The human data is minimal: one study administered IV galanin to approximately 12 healthy young men and found increased REM sleep duration with a preliminary signal for acute antidepressive effects (Murck et al., 2004; PMID 15219645). No clinical trial for sleep, depression, or any other indication has followed. This article examines why galanin's role in the sleep switch is so well characterized in animal models, what the single human study actually showed, and why translating a VLPO-specific neuropeptide into a therapy faces formidable challenges.
In This Article
Quick Facts: Galanin at a Glance
Type
Endogenous neuropeptide, 29 amino acids (human form), 30 amino acids in non-primate mammals. C-terminal amidation.
Also Known As
GAL, Galanin-29, galanin (1–29)
Generic Name
None. No pharmaceutical product exists.
Route
IV infusion (single human study). ICV injection (animal models). No oral, subcutaneous, or intranasal protocol established for sleep or any indication.
Molecular Weight
~3,164 Da (human 29-aa form)
Peptide Sequence
Human galanin: 29 amino acids with N-terminal glycine and C-terminal amidation. Named from its first and last amino acids (glycine-alanine → gal-anin) by discoverers Tatemoto and Mutt in 1983.
Endogenous Origin
Yes. Widely distributed in the central and peripheral nervous systems. Key sites: VLPO (sleep switch), locus coeruleus, dorsal raphe, hypothalamic arcuate nucleus, amygdala, hippocampus, dorsal root ganglia, and enteric nervous system.
Primary Molecular Function
Acts through three receptors: GalR1 (Gi-coupled, inhibitory—sleep-promoting, silences wake centers), GalR2 (Gq/Gi-coupled, excitatory or modulatory depending on context), GalR3 (Gi-coupled, inhibitory—implicated in mood regulation). VLPO sleep promotion operates primarily through GalR1-mediated inhibition of wake-promoting nuclei.
Active Fragment
Full-length galanin (1–29) is the primary active form. The N-terminal 15 amino acids (galanin 1–15) retain significant receptor affinity. Galanin-like peptide (GALP) is a related peptide that activates galanin receptors but with different tissue distribution.
Brand Name
None. No galanin therapeutic has been developed.
Related Compound Relationship
Galanin is functionally coupled to orexin (also in Cluster J): VLPO galanin neurons inhibit orexin neurons in the lateral hypothalamus, representing the "off switch" for orexin's wakefulness signal. Also interacts with NPY in hypothalamic feeding circuits and with CRH in stress-related pathways.
Clinical Programs
No active clinical development for galanin agonists or antagonists for sleep. GalR3 antagonists have been explored preclinically for depression and anxiety. No IND filed for any galanin-targeting compound.
WADA Status
Not on the Prohibited List
Community Interest
Essentially none. Galanin is not available from consumer peptide vendors and has no presence in biohacking or peptide self-experimentation communities. Academic interest is high in sleep neuroscience.
FDA Status
Not approved for any indication. Not in clinical development. Not available as a pharmaceutical product.
Half-Life
Plasma: ~4–7 minutes (rapid enzymatic degradation by endopeptidases). The short half-life is a significant pharmacological challenge for any therapeutic application.
Evidence Tier
3 Pilot / Limited Human Data
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Galanin?
Pronunciation: GAL-uh-nin
There is a moment every night—you may have noticed it—when your hands and feet suddenly feel warm. This is not your body heating up. It is your body dumping heat. Blood flow to the extremities increases, radiating core body heat outward, and your internal temperature drops. Within minutes, you fall asleep. For decades, sleep scientists knew that body cooling preceded sleep onset but did not understand why the same brain region that initiates sleep also triggers thermoregulation. The answer turned out to be galanin.
Galanin is a 29-amino-acid neuropeptide discovered in 1983 by Kazuhiko Tatemoto and Viktor Mutt—the same duo who discovered neuropeptide Y the year before. The name is a portmanteau of its terminal amino acids: glycine at the N-terminus and alanine at the C-terminus. It is one of the most widely distributed neuropeptides in the mammalian nervous system, involved in feeding, pain processing, seizure modulation, cognition, and mood regulation. But its most important role—at least for this cluster—is as the defining peptide of the VLPO sleep switch.
The ventrolateral preoptic area, a tiny region near the base of the hypothalamus, contains the neurons responsible for initiating and maintaining sleep. These neurons are GABAergic (they release the inhibitory neurotransmitter GABA), and they co-release galanin. When they fire, they inhibit every major wake-promoting center in the brain: the locus coeruleus (norepinephrine), the tuberomammillary nucleus (histamine), the dorsal raphe (serotonin), and the lateral hypothalamus (orexin). Simultaneously, they activate thermoregulatory circuits that cause heat dissipation—the warm hands and feet that signal sleep onset. Galanin is the molecular signature of the cells that put you to sleep.
PLAIN ENGLISH
Galanin is a peptide found throughout your nervous system, but its most important job is in a tiny brain region called the VLPO—the brain's sleep switch. When VLPO neurons fire, they release galanin and GABA to shut down the parts of your brain that keep you awake. Those same neurons also trigger the body cooling that you experience just before falling asleep—the warm hands and feet are heat radiating out of your core. Galanin marks these dual-function neurons. It was discovered in 1983 by the same scientists who discovered NPY.
Origins and Discovery
Kazuhiko Tatemoto had a technique. He had developed a chemical assay that detected C-terminal amidation—a post-translational modification common to many bioactive peptides—and was systematically mining porcine tissues for new neuropeptides. In 1982, this technique yielded NPY from pig brain. In 1983, it yielded galanin from pig intestine. The name was constructive: G (glycine, first residue) + AL (alanine, last residue) + IN (conventional peptide suffix).
Galanin's role in sleep emerged much later. The VLPO was identified as the critical sleep-promoting brain region in the 1990s by Clifford Saper and colleagues, who noted that lesions of this area produced profound insomnia in rats. The neurons in the VLPO were found to be GABAergic and galanin-expressing—making galanin the molecular marker of the sleep switch. But correlation is not causation, and it took two decades of increasingly sophisticated tools to prove that galanin neurons themselves drive sleep.
The definitive proof came in 2018. Kroeger et al. used optogenetics—genetically encoded light-sensitive channels that allow researchers to activate or silence specific neuron types with millisecond precision—to demonstrate that VLPO galanin neurons are both necessary and sufficient for sleep promotion. Low-frequency optical stimulation (1–4 Hz) of these neurons increased NREM sleep. High-frequency stimulation (>8 Hz) paradoxically caused waking—likely through conduction block. And the same neurons that promoted sleep also activated thermoregulatory heat-loss pathways, unifying two long-standing observations: sleep onset requires VLPO activity, and sleep onset is accompanied by body cooling. Both are driven by the same galanin neurons.
PLAIN ENGLISH
Galanin was found in pig intestine in 1983 by the same technique that discovered NPY. Its role in sleep was not recognized until the 1990s, when researchers identified that the brain's sleep switch was built from neurons containing galanin. The proof came in 2018 using optogenetics—literally turning sleep-switch neurons on and off with light. Activating galanin neurons slowly caused sleep. The same neurons also triggered body cooling. One set of neurons, two functions, one peptide marker.
Mechanism of Action
The VLPO Sleep Switch
The VLPO sleep circuit is a mutual-inhibition network—a "flip-flop switch" where sleep-promoting and wake-promoting centers suppress each other. Galanin's role operates at the molecular level of this switch:
VLPO → Wake center inhibition: VLPO neurons release GABA and galanin onto wake-promoting nuclei. GABA provides fast synaptic inhibition (milliseconds). Galanin provides slow, sustained neuromodulatory inhibition via GalR1 receptors on target neurons—prolonging the suppression of wakefulness beyond what GABA alone achieves. This dual neurotransmitter/neuropeptide mechanism explains why sleep, once initiated, tends to be sustained rather than flickering.
Target nuclei and their neurotransmitters: - Locus coeruleus (norepinephrine) — galanin/GalR1 inhibits ~35% of LC neurons (Luskin et al., 2023; PMID 37487094) - Tuberomammillary nucleus (histamine) — primary target for sleep maintenance - Dorsal raphe (serotonin) — modulates sleep-wake transitions - Lateral hypothalamus (orexin) — galanin neurons suppress the orexin wake signal
Thermoregulatory coupling: The same VLPO galanin neurons that inhibit wake centers also project to thermoregulatory circuits in the median preoptic area and dorsomedial hypothalamus. Activation of these projections causes peripheral vasodilation → heat loss → core temperature drop of ~1–2°F. This explains the well-documented phenomenon that a warm bath before bed improves sleep onset—not because warmth is soothing, but because the post-bath heat dissipation accelerates the VLPO-mediated cooling process that precedes sleep.
Galanin Receptor Pharmacology
GalR1: Gi-coupled (inhibitory). Mediates sleep promotion via VLPO circuit. Also mediates anxiolytic effects. Primary target for sleep-relevant galanin signaling.
GalR2: Gq/Gi dual-coupled (context-dependent). Can be excitatory (neurogenesis, trophic effects) or inhibitory depending on cell type and signaling partners. Implicated in feeding and pain modulation. Complicates drug development because GalR2 effects may oppose GalR1 effects in some circuits.
GalR3: Gi-coupled (inhibitory). Less studied. Implicated in depression and anxiety—GalR3 knockout mice show antidepressant-like behavior. GalR3 antagonists have been explored preclinically for mood disorders.
Why Galanin, Not Just GABA?
If VLPO neurons release GABA (a fast-acting inhibitory neurotransmitter), why do they also need galanin (a slower-acting neuropeptide)? The answer involves timescale and reliability:
- GABA produces rapid, brief inhibition—good for quick state transitions
- Galanin produces slow, sustained inhibition via GalR1—good for maintaining sleep state
- Together, they create a system that can both flip the switch (GABA) and hold it in position (galanin)
- In neurodegeneration that affects VLPO neurons (as in Alzheimer's disease), loss of galanin co-transmission may contribute to the sleep fragmentation that characterizes the disease
PLAIN ENGLISH
Galanin's sleep mechanism works like a two-step process. First, the sleep-switch neurons release GABA for a quick shutdown of wake centers. Then galanin provides a slow, sustained hold—keeping those centers quiet so you stay asleep rather than flickering between states. The same neurons also trigger body cooling by sending signals to thermoregulatory circuits. This is why cooling your body before bed helps you fall asleep—it mimics what your brain's sleep switch does naturally. Galanin has three receptor types, and they do different things, which is one reason it has been hard to develop into a drug.
Key Research Areas and Studies
IV Galanin in Healthy Men (Murck et al., 2004)
Study: Galanin and cortisol after intravenous galanin infusion in healthy young men. PMID: 15219645 Design: IV galanin infusion in approximately 12 healthy young male volunteers. Sleep polysomnography. Open-label. Key findings: Galanin increased REM sleep duration. Preliminary evidence for acute antidepressive efficacy (mood rating improvement). Cortisol response measured. Well-tolerated. Limitations: Very small sample (~12), healthy volunteers (not patients), open-label (no blinding), single center, single dose. Not a controlled trial for any indication. Significance: The only study administering galanin to humans and measuring sleep endpoints. Despite limitations, it is the sole piece of human data supporting galanin's sleep-modulating role.
VLPO Galanin Optogenetics (Kroeger et al., 2018)
Study: Galanin neurons in the ventrolateral preoptic area promote sleep and heat loss in mice. PMID: 30297727 Design: Optogenetic activation of genetically targeted VLPO galanin neurons in Gal-Cre mice with EEG/EMG recording and body temperature monitoring. Key findings: Low-frequency stimulation (1–4 Hz) of VLPO galanin neurons promoted NREM sleep. High-frequency stimulation (>8 Hz) caused paradoxical waking (conduction block). Galanin neuron activation simultaneously triggered heat loss via thermoregulatory projections. First causal demonstration that galanin neurons are both sleep-promoting and thermoregulatory. Significance: The definitive paper. Proved that VLPO galanin neurons are causally sufficient for sleep promotion and that sleep initiation and body cooling are driven by the same neuronal population.
Locus Coeruleus Galanin Signaling (Luskin et al., 2023)
Study: Neuronal diversity of neuropeptide signaling, including galanin, in the mouse locus coeruleus. PMID: 37487094 Design: Single-cell RNA sequencing and electrophysiology of locus coeruleus neurons. Key findings: GalR1 expressed in approximately 19% of LC noradrenergic neurons. GalR1 agonist application inhibited approximately 35% of LC NE neurons—a larger proportion than express the receptor, suggesting network-level effects. This LC inhibition reduces noradrenergic wake drive, complementing the VLPO circuit. Significance: Demonstrates that galanin's sleep-promoting effect operates through multiple targets, not just the VLPO flip-flop switch. LC inhibition by galanin is an independent mechanism for reducing arousal.
PLAIN ENGLISH
One small study gave galanin intravenously to about 12 healthy men and measured their sleep—it increased REM sleep and showed a hint of mood improvement. A much larger and more rigorous study in 2018 used optogenetics to prove that activating galanin neurons in the sleep switch causes sleep and body cooling simultaneously. A 2023 study showed that galanin also quiets the brain's main norepinephrine center—another pathway for reducing wakefulness. The animal evidence is strong and specific. The human evidence is a single small study.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “Galanin promotes sleep” | VLPO galanin neuron activation causally promotes NREM sleep in mice (Kroeger et al., 2018, PMID 30297727). IV galanin increased REM sleep in healthy men (Murck et al., 2004, PMID 15219645). | Mixed Evidence |
| “VLPO galanin neurons are the brain's sleep switch” | Optogenetic evidence demonstrates VLPO galanin neurons are causally sufficient for sleep promotion and thermoregulatory heat loss. Among the most definitive cell-type-specific sleep findings in neuroscience. | Supported |
| “Galanin triggers body cooling before sleep” | VLPO galanin neurons project to thermoregulatory circuits and their activation causes heat loss (Kroeger et al., 2018). The neurons that initiate sleep and the neurons that trigger heat loss are the same cells. | Supported |
| “Galanin has antidepressant effects” | IV galanin showed preliminary mood improvement in ~12 healthy men (Murck et al., 2004). Not replicated. Not tested in depressed patients. | Preclinical Only |
| “Galanin supplements can improve sleep” | Galanin is not available as a supplement. Even if it were, the 4–7 minute plasma half-life and blood-brain barrier penetration challenges make peripheral administration unlikely to produce CNS effects sufficient for sleep modification. | Unsupported |
| “A warm bath helps sleep because of galanin” | Body cooling after warming accelerates the VLPO-mediated thermoregulatory process that precedes sleep. The connection is biologically plausible and consistent with the Kroeger et al. findings, but no study has specifically measured galanin neuron activation after a warm bath in humans. | Mixed Evidence |
| “Galanin loss contributes to sleep problems in Alzheimer's” | VLPO neurons are among the earliest affected in Alzheimer's-type neurodegeneration. Loss of galanin co-transmission from remaining VLPO neurons could contribute to sleep fragmentation. The hypothesis is consistent with observed pathology but not directly tested. | Mixed Evidence |
| “GalR1 agonists could treat insomnia” | Biologically rational—GalR1 mediates VLPO sleep promotion and LC inhibition. But no GalR1-selective agonist has been developed for clinical use. Receptor subtype selectivity and CNS delivery are major challenges. | Preclinical Only |
| “Galanin is the most important sleep peptide” | Galanin marks the VLPO sleep-promoting neurons, but sleep regulation involves many systems (orexin, adenosine, melatonin, GABA, prostaglandin D2, cortistatin). Galanin is critically important but not singular. | Mixed Evidence |
| “Galanin regulates appetite” | Yes. Galanin stimulates feeding, particularly fat preference, through hypothalamic circuits (arcuate nucleus). This is separate from its sleep role. A galanin-based sleep drug might have appetite side effects. | Supported |
| “Galanin is involved in pain” | Yes. Galanin modulates nociception in dorsal root ganglia and spinal cord. It has both pro- and anti-nociceptive effects depending on receptor subtype and location. Not directly relevant to sleep but relevant to pharmacological complexity. | Supported |
| “Galanin could explain why exercise improves sleep” | Exercise increases galanin expression in some brain regions in rodent studies. Whether this increase contributes to post-exercise sleep improvement is speculative. The link between exercise, galanin, and sleep has not been directly tested. | Preclinical Only |
The Human Evidence Landscape
The human evidence for galanin consists of a single study: Murck et al. (2004), which administered IV galanin to approximately 12 healthy young men and measured polysomnographic sleep outcomes. The study found increased REM sleep duration and a preliminary signal for mood improvement. This is the entirety of the human data.
What the Murck Study Shows
The study is real, published in a reputable journal (Psychoneuroendocrinology), and reports a genuine finding: exogenous IV galanin modulated sleep architecture in humans. The REM increase is consistent with galanin's known effects on sleep circuitry. The mood improvement signal is consistent with the theory that sleep modulation can have rapid antidepressant effects (similar to the mechanism proposed for therapeutic sleep deprivation).
What the Murck Study Does Not Show
It does not demonstrate that galanin treats insomnia—the subjects were healthy, not insomnia patients. It does not demonstrate sustained effects—it was a single-dose study. It does not demonstrate safety beyond a single exposure in young healthy men. It was not blinded or placebo-controlled, which means the mood findings are particularly vulnerable to expectancy effects. And it has not been replicated—no other group has administered galanin to humans for any purpose in the 20+ years since publication.
The Translational Gap
The distance between the animal evidence and the human evidence is enormous. The optogenetics papers (Kroeger 2018, Luskin 2023) provide some of the most definitive cell-type-specific evidence in sleep neuroscience—you can literally turn sleep on and off by activating galanin neurons with light. But this specificity is the problem: the therapeutic effect requires galanin signaling in the VLPO and locus coeruleus specifically, not systemic galanin exposure. Peripheral galanin administration (IV, SC, intranasal) would activate galanin receptors throughout the body—in gut, in nociceptive neurons, in feeding circuits—producing off-target effects while uncertain amounts reach the VLPO.
No pharmaceutical company has announced a galanin receptor-targeting program for sleep. The receptor complexity (three subtypes with partially opposing effects), the short half-life (minutes), and the CNS delivery challenge make galanin a difficult drug target despite beautiful biology.
PLAIN ENGLISH
One study in about 12 healthy men is the total human evidence for galanin and sleep. The animal evidence is world-class—optogenetics proved that galanin neurons are the brain's sleep switch—but translating this to a drug means getting a short-lived peptide to the right brain region without activating galanin receptors in the gut, pain circuits, and appetite centers along the way. No drug company is trying.
Safety, Risks, and Limitations
Human Safety Data
IV galanin was well-tolerated in the Murck et al. study (approximately 12 healthy young men, single infusion). No serious adverse events reported. This is the extent of human safety data.
Theoretical Risks
Appetite stimulation: Galanin stimulates feeding behavior, particularly fat-preferring intake, through hypothalamic GalR1 activation. Systemic galanin exposure could increase appetite.
Pain modulation: Galanin has complex effects on nociception—it can be analgesic or pro-nociceptive depending on receptor subtype, spinal level, and injury state. Systemic galanin could produce unpredictable pain-related effects.
Seizure modulation: Galanin is anticonvulsant (GalR1 agonism suppresses seizure activity in animal models). While this is theoretically beneficial, the interaction between sleep-promoting and anticonvulsant effects of a galanin drug would need careful characterization.
Rapid clearance: Galanin's plasma half-life of 4–7 minutes means that any peripheral formulation would require either continuous infusion or a stabilized analog to maintain therapeutic levels—adding pharmacological complexity.
PLAIN ENGLISH
Galanin was safe in the one small study that tested it in humans. The main concerns for any future drug are that galanin also affects appetite (could increase eating), pain (unpredictable effects), and seizures (suppresses them, which is actually beneficial but would need monitoring). And the peptide breaks down in blood within minutes, so maintaining effective levels would require either constant infusion or an engineered longer-lasting version.
Legal and Regulatory Status
Galanin has no regulatory status as a pharmaceutical. It is not FDA-approved, not in clinical development, and not classified as a controlled substance. Research-grade galanin is available from laboratory peptide suppliers (Bachem, Tocris, Phoenix Pharmaceuticals) for institutional research use.
Galanin is not available from consumer peptide vendors and is not marketed as a supplement, sleep aid, or nootropic.
WADA does not list galanin on its Prohibited List.
Research Protocols and Formulation Considerations
Human Research Protocol (Murck et al.)
| Parameter | Detail |
|---|---|
| Compound | Synthetic human galanin (1–29) |
| Route | IV infusion |
| Subjects | ~12 healthy young men |
| Measurement | Polysomnography (sleep stages, REM duration) |
| Tolerability | Well-tolerated, no serious adverse events |
Animal Research Protocols
| Parameter | Detail |
|---|---|
| Optogenetics (Kroeger) | Viral ChR2 expression in VLPO galanin neurons; optical fiber stimulation 1–4 Hz (sleep) vs. >8 Hz (wake) |
| ICV injection | Galanin 0.1–3.0 nmol; EEG/EMG recording |
| LC electrophysiology (Luskin) | GalR1 agonist bath application; patch-clamp recording of LC NE neurons |
Storage
Research-grade galanin: lyophilized powder at −20°C (−4°F). Reconstituted in saline. Use within hours—short peptide half-life.
Dosing in Published Research
The following table summarizes dosing protocols for Galanin as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
Published Research Dosing
| Parameter | Detail |
|---|---|
| Route | IV infusion (human), ICV (animal) |
| Human IV dose | Not specified in published abstract; single infusion protocol |
| Animal ICV dose | 0.1–3.0 nmol galanin in rats |
| Therapeutic dose | Does not exist — no therapeutic has been developed |
| Half-life limitation | Plasma ~4–7 minutes; would require stabilized analog for sustained effect |
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
Galanin has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
Why This Section Is Nearly Empty
Galanin is not used in self-experimentation communities. It is not sold by consumer peptide vendors, has no established self-dosing protocol, and would be pharmacologically impractical for self-administration due to its 4–7 minute plasma half-life. The only human administration was an IV infusion in a clinical research setting. There are no forum discussions, community protocols, or anecdotal reports of galanin self-experimentation for sleep or any other purpose.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Galanin combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Galanin with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How Galanin Compares
Galanin belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Sleep, Stress & Recovery cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Primary Application | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Neuropeptide Y | Neuropeptide (36 aa) | Tier 2 — Clinical Trials | Eyes Open | Y1 receptor anxiolysis, CRH antagonism, HPA axis modulation | Stress resilience, PTSD, anxiety | Phase Ib RCT (intranasal, PTSD) + RCT (MDD) — ~54 patients total | Not approved | Not prohibited | Small early-phase trials; intranasal BBB penetration uncertain |
| Desmopressin | Synthetic vasopressin analog (9 aa, cyclic) | Tier 1 — Approved Drug | Strong Foundation | V2 receptor agonism → antidiuresis → reduced nocturnal urine volume | Nocturnal enuresis, nocturia, central DI | Cochrane review (47 RCTs, N=3,448) + Phase III nocturia (N=757) | Approved (multiple formulations, 1978+) | Not prohibited | Hyponatremia risk; nasal spray withdrawn for enuresis (2007) |
| Corticotropin-Releasing Hormone | Neuropeptide (41 aa) | Tier 4 — Preclinical (therapeutic) | Eyes Open | HPA axis master switch — CRH-R1 activation → ACTH → cortisol | Understanding stress biology; CRH-R1 antagonists for depression (failed) | Biomarker studies (elevated CSF CRH in depression); CRH-R1 antagonist trials failed | Diagnostic only (Acthrel for Cushing's differentiation) | Not prohibited | CRH-R1 antagonists failed in depression trials despite strong mechanistic rationale |
| Orexin | Neuropeptide pair (OxA 33 aa + OxB 28 aa) | Tier 1 — Approved Drug | Strong Foundation | OX1R/OX2R wake promotion; loss → narcolepsy | Insomnia (via DORAs); narcolepsy diagnosis/treatment | 3 Phase III DORA trials (N=4,945 total); CSF orexin diagnostic for narcolepsy | 3 DORAs approved (suvorexant 2014, lemborexant 2019, daridorexant 2022) | Not prohibited (DORAs may be relevant) | DORAs are small molecules not peptides; orexin agonists for narcolepsy still in development |
| Cortistatin | Neuropeptide (14–17 aa, somatostatin-related) | Tier 4 — Preclinical Only | Eyes Open | Cortical activity depression → slow-wave sleep induction; ACh antagonism | Deep sleep promotion (theoretical) | None | Not approved | Not prohibited | No human data; single research group; somatostatin receptor cross-reactivity |
| Galanin | Neuropeptide (29 aa) | Tier 3 — Limited Human Data | Eyes Open | VLPO sleep-switch activation; LC noradrenergic inhibition | Sleep initiation; potential antidepressant | 1 IV study in healthy men: increased REM, preliminary antidepressant signal | Not approved | Not prohibited | Single small human study; 3 receptor subtypes with opposing effects complicate targeting |
| PACAP | Neuropeptide (27–38 aa, VIP family) | Tier 2 — Clinical Trials | Eyes Open | PAC1/VPAC receptor activation → stress amplification + migraine | Migraine prevention (via anti-PAC1 antibody); PTSD genetics | Phase 2 anti-PAC1 antibody (migraine, positive); PTSD genetic association | Not approved (anti-PAC1 Lu AG09222 Phase 2b ongoing) | Not prohibited | Therapeutic = blocking PACAP not administering it; stress/sleep applications undeveloped |
| Melanin-Concentrating Hormone | Neuropeptide (19 aa) | Tier 4 — Preclinical Only | Eyes Open | MCH neuron activation → selective REM sleep promotion | REM sleep regulation; narcolepsy (MCHR1 antagonism) | None clinical | Not approved; HBS-102 IND stage (narcolepsy) | Not prohibited | No human clinical data; obesity MCHR1 programs failed; narcolepsy IND not advanced |
| Cosyntropin | Synthetic ACTH fragment (24 aa) | Tier 1 — Approved Drug | Strong Foundation | MC2R activation → adrenal cortisol production | Adrenal insufficiency diagnosis (ACTH stimulation test) | Millions of diagnostic tests performed worldwide since 1970 | Approved diagnostic (Cortrosyn, 1970). Synacthen Depot therapeutic (EU/UK). | Prohibited (S2 — ACTH analogs) | US diagnostic only; therapeutic use primarily outside US |
Frequently Asked Questions
What is galanin?
Galanin is a 29-amino-acid neuropeptide found throughout the central and peripheral nervous systems. It regulates sleep, appetite, pain, seizures, and mood. Its most clinically relevant role is as the defining peptide of the VLPO neurons—the brain's sleep switch—which initiate sleep and trigger the body cooling that precedes sleep onset.
How does galanin help with sleep?
VLPO neurons release galanin (along with GABA) to inhibit wake-promoting brain centers including the locus coeruleus (norepinephrine), tuberomammillary nucleus (histamine), and raphe nuclei (serotonin). Galanin provides sustained inhibition that keeps these centers quiet, maintaining sleep once GABA initiates the state transition.
Why do my hands get warm before I fall asleep?
VLPO galanin neurons simultaneously initiate sleep and activate thermoregulatory circuits that cause peripheral vasodilation—blood flows to your extremities, radiating core body heat outward. Your hands and feet feel warm because they are dumping heat. Your core temperature drops 1–2°F, which is a physiological requirement for sleep onset. This dual function of galanin neurons was proven by optogenetics in 2018.
Is there a galanin sleep supplement?
No. Galanin is not available as a consumer product. Even if it were, its 4–7 minute half-life in blood and uncertain brain penetration after peripheral administration make it impractical as a supplement. The therapeutic potential of galanin would require a stabilized, brain-penetrating analog or a GalR1-selective small molecule—neither exists.
Has galanin been tested in humans?
Once. A single study (Murck et al., 2004) gave IV galanin to about 12 healthy young men and found it increased REM sleep and showed a possible antidepressant effect. The study was small, open-label, and has not been replicated. No clinical trial for insomnia, depression, or any other condition has been conducted.
Does a warm bath before bed work because of galanin?
Partially. A warm bath raises skin temperature, causing peripheral vasodilation. After the bath, accelerated heat loss drops core temperature—mimicking the VLPO-mediated thermoregulatory process that precedes sleep. The galanin connection is that the same neurons driving this heat loss also drive sleep initiation. The bath effectively jump-starts a physiological process that galanin neurons normally control.
Why hasn't galanin been developed into a drug?
Three main barriers. First, galanin has three receptors with different and sometimes opposing effects—targeting one without the others is difficult. Second, the peptide's 4–7 minute half-life makes it impractical for chronic dosing. Third, the sleep effect requires specific brain region targeting (VLPO, locus coeruleus), and systemic galanin would also activate receptors in appetite, pain, and gut circuits.
How does galanin relate to orexin?
Galanin and orexin are on opposite sides of the sleep-wake switch. Orexin neurons in the lateral hypothalamus promote wakefulness. VLPO galanin neurons inhibit orexin neurons (among other wake centers) to initiate sleep. They are the yin and yang of the flip-flop switch model of sleep regulation. Three FDA-approved drugs block orexin to treat insomnia. No drug targets galanin.
Could galanin help with Alzheimer's-related sleep problems?
This is a biologically plausible but untested hypothesis. VLPO neurons are among the earliest affected by Alzheimer's pathology, and sleep fragmentation is a prominent early symptom. Loss of VLPO galanin signaling could contribute to this. However, no study has tested galanin-based interventions in Alzheimer's patients.
Is galanin the same as GABA?
No. GABA is a small-molecule neurotransmitter that produces fast synaptic inhibition. Galanin is a neuropeptide that produces slow, sustained neuromodulatory inhibition. VLPO sleep neurons release both: GABA for the rapid state transition from wake to sleep, galanin for maintaining the sleep state. They work together but through different mechanisms and timescales.
Does exercise increase galanin?
In rodent studies, exercise increases galanin expression in some brain regions, particularly the locus coeruleus. Whether this contributes to the sleep-improving effects of exercise is speculative. The specific link between exercise, brain galanin levels, VLPO function, and sleep quality has not been tested in humans.
Could galanin explain why some people are naturally good sleepers?
Possibly. Genetic variation in galanin, its receptors, or VLPO neuron density could contribute to individual differences in sleep quality. Some genome-wide association studies have identified galanin receptor variants associated with sleep traits. But this is correlational and has not been translated into clinical insights.
Summary of Key Findings
Galanin is the molecular signature of the brain's sleep switch. The VLPO galanin neurons that initiate sleep have been identified, optogenetically manipulated, and shown to simultaneously promote NREM sleep and trigger the body cooling that precedes sleep onset. This dual function—sleep initiation and thermoregulation—is among the most elegant findings in modern sleep neuroscience and explains why your body temperature drops before you fall asleep.
The clinical evidence does not match the preclinical elegance. One study, approximately 12 healthy young men, IV galanin, increased REM sleep, a hint of mood improvement. That is it. Twenty years of beautiful animal work, one small human study, zero clinical trials, zero drug development programs. The reasons are pharmacological: three receptor subtypes with different effects, a 4–7 minute half-life, the need for brain-region-specific delivery, and off-target risks in appetite, pain, and gut circuits.
For Peptidings readers, galanin is valuable as biology education—understanding why body cooling helps sleep, why the sleep switch works as a flip-flop, and why VLPO neuron loss in aging and neurodegeneration disrupts sleep. It is not currently a therapeutic opportunity.
Verdict Recapitulation
Evidence Tier 3 — Limited Human Data. One small IV study in healthy men showing REM sleep increase. Definitive optogenetic evidence in animal models.
Verdict: Eyes Open. The sleep-switch biology is among the best characterized in neuroscience—proven causally by optogenetics. The clinical translation has not been attempted, and the pharmacological challenges are formidable. Beautiful science. No medicine.
For readers considering Galanin, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Galanin
Further Reading and Resources
If you want to go deeper on Galanin, the evidence landscape for sleep, stress & recovery peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Sleep, Stress & Recovery Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Galanin — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Murck H, et al. Galanin and cortisol secretion after intravenous challenge with galanin in healthy young men. Psychoneuroendocrinology. 2004;29(7):953–960 PubMed
- Kroeger D, et al. Galanin neurons in the ventrolateral preoptic area promote sleep and heat loss in mice. Nat Commun. 2018;9(1):4129 PubMed
- Luskin AT, et al. Neuronal diversity of neuropeptide signaling, including galanin, in the mouse locus coeruleus. PNAS. 2023;120(30):e2304124120 PubMed
- Tatemoto K, et al. Galanin—a novel biologically active peptide from porcine intestine. FEBS Lett. 1983;164(1):124–128 PubMed
- Saper CB, et al. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437(7063):1257–1263 PubMed
- Lang R, et al. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol Rev. 2015;67(1):118–175 PubMed
DISCLAIMER
Galanin is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 09, 2026. Next scheduled review: October 06, 2026.